TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06794918

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercise
Description: Researchers will teach individuals pge exercises to help them relax
Study: NCT05910372

Intervention type: OTHER
Intervention: Color Comparison Task
Description: Participants are presented with a series of colored squares and are instructed to compare the colors of two sequentially presented stimuli.

Intervention type: OTHER
Intervention: Color Comparison Task
Description: Participants are presented with a series of colored squares and are instructed to compare the colors of two sequentially presented stimuli.

Intervention type: OTHER
Intervention: N-back Task
Description: Participants are presented with a sequence of letters and they must indicate whether the current stimulus matches the one presented 2 steps back in the sequence.

Intervention type: OTHER
Intervention: N-back Task
Description: Participants are presented with a sequence of letters and they must indicate whether the current stimulus matches the one presented 2 steps back in the sequence.
Study: NCT05699499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KeryFlex
Description: KeryFlex is a painless, in-office cosmetic application of artificial nails which improves the appearance of nails damaged by various nail disorders. The composite resin creates a flexible, nonporous nail that allows the remaining natural nail to grow. KeryFlex is a three-step procedure that takes 10 to 15 minutes for a typical nail. At least 15% of the existing nail must be present for the resin application. The material used in KeryFlex is approved as a cosmetic by the FDA.
Study: NCT04647578

Intervention type: DEVICE
Intervention: GT3X Actigraph accelerometer.
Description: GT3X Actigraph accelerometer during 7 days
Study: NCT06382584

Intervention type: PROCEDURE
Intervention: Femoral fracture surgery
Description: Hip fracture surgery
Study: NCT02503553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Option grid for cerebral aneurysm treatment
Description: Patients will receive an option grid during the preoperative visit. They will be given the chance to read it and ask questions. The option grid will include head to head comparative answers for the two interventions available for cerebral aneurysms (surgical clipping and endovascular coiling). The interaction with the aneurysm surgeon will be voice recorded.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
Study: NCT04286321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zero hard-boiled egg
Description: No eggs will be consumed on test day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two egg whites
Description: Two egg whites will be consumed on test day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two hard-boiled eggs
Description: Two eggs will be consumed on test day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetable oil
Description: Vegetable oil will be consumed on test day
Study: NCT05118165

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement with protein
Description: Will be included protein supplements in the preoperative diet.
Study: NCT06795919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: : delayed surgical repair of alveolar cleft using particulate cortico-cancellous anterior iliac bon
Description: skin incision was marked 2-4 cm from the crest to anterior iliac spine height. This is done to avoid pain at the beltline if the incision is made directly over the anterior ilium. As well as avoid injury to the lateral femoral cutaneous nerve. After the anatomical marking are drawn using betadine solution, the site is injected with local anesthesia at the subcutaneous level. The skin incision line is made parallel to the iliac crest and posterior to the anterior iliac spine. Scalpel blade number 10 is used. The incision of the skin and subcutaneous fat was performed. Blunt dissection is carried out at the level of subcutaneous tissues to separate the fascia from fat. Cautery is used to control any hemorrhage. Using a number 15 blade, fascia was incised which covers the iliac spine. A hypo vascular plane was identified. It is located over the anterior iliac spine, as well as between the insertions of tensor fascia laterally and the external and the transverse abdominal muscles medially
Study: NCT05484934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative post mastectomy surgery
Description: Implantation of the Nipple-Areolar Complex (NAC) Reconstruction Using a Decellularized Donor NAC Graft (DCLNAC)
Study: NCT04588415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bereavement Virtual Support Group
Description: Family members who experience loss will be invited to attend a virtual support group (VSG) led by Bereaved Families of Ontario- Ottawa (BFO). In pre-COVID-19 times, BFO presented monthly Support and Share nights with guest speakers, followed by breakout peer support groups for all different types of losses: loss of child, spouse, parent, loss by suicide, etc. These groups are facilitated by trained volunteers with a shared loss and include between 75 and 150 participants. These Support and Share Nights serve as intake sessions- interested participants from the breakout groups can attend Closed Groups where a smaller group of participants (up to 12) explore their grief more deeply. These run over 8-10 consecutive weeks with the same group of participants. They are led by trained facilitators who have experienced similar losses. Each week has a different theme, based on evidence-based components of bereavement support (e.g. writing a letter to the deceased).
Study: NCT04973683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL101
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery
Study: NCT06656117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elliptical training
Description: • Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: • Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.
Study: NCT06653751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reminder App
Description: he purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.
Study: NCT06656650

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Commensality groups
Description: Participants will attend at least 3 out of 6 commensality groups over the course of 6 months.
Study: NCT06661330

Intervention type: OTHER
Intervention: Behavioral Treatment
Description: Participants followed a 6-month hypocaloric Mediterranean-style diet, reducing energy intake by approximately 600 kcal/day. The diet emphasized fruits, vegetables, whole grains, and fish, while limiting red meat and processed foods. Additionally, participants were required to perform moderate physical activity, including 50 minutes of aerobic exercise, 3 times a wee
Study: NCT06792513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear Aligner
Description: In this intervention, clear aligners were digitally designed using three-dimensional models for the upper jaw. Attachments were applied to the patients, specifically placed on the incisors exhibiting a crossbite relationship and on the permanent first molars in the posterior region. The series of clear aligners were replaced every 10 days. The aligners were used full-time, except during meals and tooth brushing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labiolingual Spring Hawley Appliance
Description: In this intervention, a custom-made labiolingual spring Hawley appliance was designed for the upper jaw. It included two Adams clasps, a vestibular arch, and an active labiolingual spring positioned on the palatal side of the incisor in crossbite. The spring was activated every 10 days. The appliance was used full-time, except during meals and tooth brushing.
Study: NCT06784284

Intervention type: OTHER
Intervention: Glasgow Outcome Scale -Extended (GOSE)
Description: Questionnaire to cotate the neurological deterioration following mild head trauma. Score from 1 to 8, the higher the number the better the outcome
Study: NCT06794021

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement with Proprietary Herbal Extract Blend and GABA
Description: Eligible subjects will receive active product to take daily for seven days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible subjects will receive Placebo to take daily for seven days
Study: NCT06797102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Exercises
Description: Patients in this group received a neuromuscular training protocol along with general treatment for 10 minutes. This included hot packs, lumbar stretches, and ergonomic posture correction divided over 6 weeks The exercises performed included squatting, single leg stance, and balance reach leg and arm exercises with 10 repetitions each. They also did lunge exercises with five repetitions bilaterally, step up and down exercises with 10 repetitions, single leg standing on a balance mat with 10 repetitions and a 10-second hold, single board exercises, and single leg stance with weights and eyes closed for five minutes with a 10-second hold. Additionally, they stood on a wobble board with eyes closed five times with a 10-second hold. The protocol included running on a treadmill and trampoline for five minutes per day, running figure-of-eight patterns, and agility drills at a slow speed for five minutes each.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Close Chain Exercises
Description: Patients in this group received closed chain exercises for core strengthening along with general treatment for 10 minutes, including hot packs, lumbar stretches, and ergonomic posture correction, divided over 6 weeks. The exercises included sets of squats, lunges, leg presses, wall squats, standing heel raises on a single leg, and single leg dead lifts. Each treatment session lasted 60 minutes, incorporating a warm-up and cool-down period of 10 minutes.
Study: NCT06395636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infection-Prediction Algorithm
Description: This machine learning algorithm will be developed(Aim1a) and validated(Aim 1b) using the participant Fitbit data and survey results collected during Aim 1. In Aim 2 the algorithm will be used in real time to predict postoperative infection.
Study: NCT05705765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suspension training
Description: Training with suspension devices. 12 sessions of 40-45 min in four weeks.
Study: NCT06658964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: JMKX003142 and itraconazole
Description: JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning.~Itraconazole：Dose: 200mg once；Day5-Day7 and Day9-Day11, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: JMKX003142 and rifampicin
Description: JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning.~Rifampicin：Dose: 600mg once；Day5-Day13 and Day15-Day17, QD
Study: NCT06659666

Intervention type: DEVICE
Intervention: COPD Optimiser
Description: Patients will receive enhanced usual medical care as determined by their physician. The study visit is a standard consultation supported by the COPD Optimiser webtool. The extra elements added to the COPD consultation are the use of the COPD Optimiser and a short questionnaire directly following the consultation on the patient's experience with the COPD Optimiser. Patients can additionally consent to two optional elements: 1) a determination of blood eosinophil count using a point of care test and 2) a brief interview on their experience with the COPD Optimiser. this tool creates an overview of fac- tors and characteristics that may be associated with suboptimal COPD and provides GOLD guideline-based management suggestions. Implementation of the COPD Optimiser will sup- port healthcare professionals in providing optimal care for their COPD patients by providing individualized GOLD-guided management suggestions.
Study: NCT06661863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar ridge preservation with bioactive glass
Description: Bioactive glass grafted into alveolar preservation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar ridge preservation with autologous bone
Description: Autologous bone graft in alveolar ridge preservation.
Study: NCT06658288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound Training
Description: 12 participants will be in experimental group A giving them rebound training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraband resistance exercise
Description: 12 participants will be in experimental group A giving them theraband resistance exercise with different band resistnce.
Study: NCT06661707

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sonar guided Quadratus Lumborum block
Description: The probe will be tilted down the lateral abdomen to identify a bright hyperechoic line that represents the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of (0.2 mL/kg of 0.25% bupivacaine per side) will be applied without exceeding the toxic dose 3 mg/kg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sonar guided Ilioinguinal/Iliohypogastric block
Description: The ultrasound linear probe will be placed over the anterior superior iliac spine with the superior margin of the transducer pointed directly in an oblique plane toward the umbilicus. The iliohypogastric nerve will be seen medial to the ilioinguinal nerve. The overlying skin will be prepared with antiseptic solution and 21 gauge 120mm Locoplex Sono Tap cannula will be advanced using an in-plane approach from a point just below the inferior border of the transducer toward the ilioinguinal nerve as it lies within the facial plane between the internal abdominal oblique and transverse abdominis muscles.~After negative aspiration, (0.2 mL/kg of 0.25% bupivacaine per side) will be injected without exceeding the toxic dose of 3 mg/kg
Study: NCT06659172

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: taVNS
Description: transauricular vagus nerve stimulation
Study: NCT06797375

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RLYB116 for Injection
Description: RLYB116 is a small protein composed of an Affibody® Z-domain that binds with high affinity to C5, inhibiting terminal complement activation, and an albumin binding domain (ABD) that extends the effective plasma half-life of the protein by targeting serum albumin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLYB116 for Injection
Description: RLYB116 is a small protein composed of an Affibody® Z-domain that binds with high affinity to C5, inhibiting terminal complement activation, and an albumin binding domain (ABD) that extends the effective plasma half-life of the protein by targeting serum albumin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLYB116 for Injection
Description: RLYB116 is a small protein composed of an Affibody® Z-domain that binds with high affinity to C5, inhibiting terminal complement activation, and an albumin binding domain (ABD) that extends the effective plasma half-life of the protein by targeting serum albumin.
Study: NCT06247631

Intervention type: OTHER
Intervention: STOP BANG
Description: The STOP-Bang Questionnaire is intended to give physicians an easy-to-use tool to identify people who might have obstructive sleep apnea (OSA). The questionnaire consists of eight yes-or-no questions based on the major risk factors for OSA. A STOP-Bang score of 2 or less is considered low risk, and a score of 5 or more is high risk for having either moderate or severe OSA. For people who score 3 or 4, doctors may need to perform further assessment to determine how likely they are to have OSA.

Intervention type: OTHER
Intervention: STOP BANG
Description: The STOP-Bang Questionnaire is intended to give physicians an easy-to-use tool to identify people who might have obstructive sleep apnea (OSA). The questionnaire consists of eight yes-or-no questions based on the major risk factors for OSA. A STOP-Bang score of 2 or less is considered low risk, and a score of 5 or more is high risk for having either moderate or severe OSA. For people who score 3 or 4, doctors may need to perform further assessment to determine how likely they are to have OSA.
Study: NCT06797037

Intervention type: OTHER
Group type: OTHER
Intervention: Decentralised Pathway Coordinated by the Advanced Practice Nurse
Description: For each patient enrolled in the study: a decentralised treatment delivery route will be organised. To achieve this, two visits will be planned by the investigating centre's Advanced Practice Nurse (APN) and carried out at the patient's home by a service-providing nurse. During these visits, the APN will take the patient's vital signs before handing over the treatment.~In addition, for the purposes of the study, during the 2nd visit the patient will be asked to complete a satisfaction questionnaire.
Study: NCT06792656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized Forest Therapy session (120 min)
Description: standardized, 2-hrs Forest Therapy session following the INFTA Forest Therapy Guiding Sequence
Study: NCT06795256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Percussion and position change in retrograde intrarenal surgery
Description: To evaluate the effectiveness of this homework on stone clearance rates after RIRC by giving instructions to the patient in the home environment and suggesting percussion (tapping) and movement/position changes to help spontaneous stone passage.
Study: NCT06795009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg\^m2 intravenous over 3 hours.
Study: NCT06659172

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: taVNS
Description: transauricular vagus nerve stimulation
Study: NCT06660914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexible Ureteroscopy
Description: Ureteroscopic lithotripsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Ureteroscopy
Description: Ureteroscopic lithotripsy
Study: NCT06662331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Sagittal Split Osteotomy
Description: A surgical procedure to correct dentofacial deformities

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Sagittal Split Osteotomy
Description: A surgical procedure to correct dentofacial deformities
Study: NCT06660927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: liac Bifurcation Stent Graft System
Description: to evaluate the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System for Endovascular Repair of Common Iliac Artery Aneurysms(CIAA)
Study: NCT06795009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg\^m2 intravenous over 3 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg\^m2 intravenous over 3 hours.
Study: NCT06793488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg
Description: Disulfiram will be used in Participants with Alcohol Use Disorder only to facilitate abstinence.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: functional MRI
Description: Participants will undergo fMRI scanning. Participants with alcohol use disorder will undergo scanning after 1 week and 3 months of disulfiram maintenance. Healthy volunteer participants will undergo scanning once.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: Participants will undergo fMRI scanning. Participants with alcohol use disorder will undergo scanning after 1 week and 3 months of disulfiram maintenance. Healthy volunteer participants will undergo scanning once.
Study: NCT06659991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alcohol condition
Description: Ethanol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alcohol condition
Description: Ethanol

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control condition
Description: sparkling water

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control condition
Description: sparkling water
Study: NCT06661317

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention